Approved drugs with CNS demyelination side effect., page-24

What is hilarious is your constantly talking about CQ toxicity. The FDA said nothing about CQ causing toxicity in Reach2HD and that being the cause of not lifting the PCH on PBT2. Prana never made such a public statement about CQ. Once again you need to be reminded that the reason for the PCH was the question of PBT2 (not CQ) dosage increase to safely improve efficacy.

You had better pray that there was no actual toxicity by PBT2 in Reach2HD Phase II that was not revealed by Prana and the Huntington Study Group's principal investigator. Until now and your CQ compulsion, that thought had not entered anyone else's mind.

I am not objecting to "this thread". I am objecting to you and your methods of obfuscating Prana's true problems, and replacing them with your imaginations about CQ. FYI, I did not report you for "bullying". One of your many errors has always been ignorance of the Disclaimer at the bottom of this page.